A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
Latest Industry News & Trends
8/20/2026
MeetingNewsletterRetinaSurgical
ASRS Meeting Shines Light on Ingenuity of Retina Surgeons Around the Globe
The 2026 annual meeting of the American Society of Retina Specialists (ASRS), held in mid-July at the Palais des Congrès in Montreal, Quebec, opened with a deep dive into surgery. The first day off...
8/20/2026
NewsletterRetina
Biosimilars, Longer-Acting Treatments Depress Exudative Retinal Pharma Revenue
Total manufacturers’ revenue from pharmaceuticals for exudative retinal diseases are on course to decline for the second year in a row—a first since the introduction of anti-VEGF therapy in 2004. M...
8/20/2026
LandscapeNewsletter
Ophthalmic Market Poised for Steady Growth Amid Digital Shift, Rising Demand
Ophthalmology continues to expand as global demand for eye care rises, digital technology moves deeper into clinical workflows, and manufacturers push new approaches to diagnosis and treatment. The...
8/20/2026
DealsFundingNewsletter
AI Funding Boom Reshapes Venture Capital as Ophthalmology Investment Holds Steady
Record venture capital investment in the first half of 2026 was driven by artificial intelligence (AI) mega-rounds, while ophthalmology continued to draw steady investor interest. AI dominated H1-2...
8/20/2026
AcquisitionsDealsNewsletterRetina
Tarsus Enters Retina Sector with Two Acquisitions that Could Top $1 Billion
Tarsus Pharmaceuticals, maker of Xdemvy drops for Demodex blepharitis, has ventured into the retina sector recently with two acquisitions that could end up topping $1 billion. Tarsus said its deals...
8/20/2026
CornealDiagnosticNewsletterRegulation
Select US FDA Approvals and Clearances in July 2026
The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in July 2026, according to the agency’s database. iHealthscreen received clearance for its iPredi...
8/20/2026
NewsletterPresbyopiaRegulationRetina
PDUFA Dates for Ophthalmic Drug Candidates, August 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
8/20/2026
NewsletterRegulationRetina
US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD
Outlook Therapeutics announced July 24 that it had gained US FDA approval for Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). The news comes after years of regulato...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.